Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment.

Jessé Lopes da Silva Fabiana Resende RodriguesGuilherme Gomes de MesquitaPriscila Valverde FernandesLuiz Claudio Santos Thuler Andreia Cristina de Melo

Published in: Breast cancer (Dove Medical Press) (2021)

No IHC biomarker evaluated showed a significant association with a response or survival outcomes in TNBC patients. Clinical stage, LNR and RCB stood out for strongly influencing survival.

Keyphrases

end stage renal disease
ejection fraction
peritoneal dialysis
lymph node
rectal cancer
patient reported outcomes
squamous cell carcinoma
locally advanced
radiation therapy
free survival